NeoDynamics Newsletter, May 2022

We are in the middle of May, which is the month with the most medical science meetings. Coming from only being able to meet virtually for two years, we can now finally have real meetings where we can meet customers, have workshops with demonstrations of NeoNavia and we can take up inquiries which are followed up in the hospitals. This is extremely important operating in medical technology and having a completely new biopsy system. 

As always, it is encouraging to see that once people try the system and hear about our clinical programme, they are keen to evaluate the system in their hospital, with colleagues. We have important meetings in May and June, in all our markets. We have moved our company to the Nasdaq First North Growth Market – which is an important milestone, paving the way for continued growth.

Anna Eriksrud, CEO of NeoDynamics

What are the benefits of our PULSE system? 

Expert MD Marc Thill, AMK Hospital Frankfurt, gives a presentation on the PULSE technology and its benefits in clinical practice, in this video. This was part of the presentation in November 2021 at the BSBR in the UK. He also presented further exciting data in Savannah at the SBI/ACR meeting, on May 16, 2022, as detailed below.

Watch the video here!

PULSE presented in Savannah

As previously reported, our clinical data from the PULSE study was accepted for an oral presentation at SBI / ACR, Society of Breast Imaging / American College of Radiologists.

This week, Professor Thill presented the subgroup analysis, of the PULSE study, in Savannah on May 16th. Professor Thill was also available at the NeoDynamics booth, where he was able to answer further questions on the study. 

“In the PULSE study we described characteristics of each axillary biopsy case in a detailed way. Fifty patients in the interim data set showed parameters indicating a challenging procedure such as close distance of the lymph node to a blood vessel, thoracic wall, or muscle. A separate analysis in this sub-group showed a procedure success rate of 96% and low rate of adverse events with only one minor hematoma and two cases of pain, none of which required further treatment. The users reported that pulses facilitated control during needle insertion in 94% of cases and stabilization of the target lesion during needle insertion in 92% of cases. The reported results in these challenging cases further underline the strong performance of the NeoNavia device,” says Professor Marc Thill in our press release. 

Spring meeting in Sweden

The Swedish Association of Breast Radiologists, SFBR, had its spring meeting in Stockholm in May where NeoDynamics were present. NeoDynamics held workshops for the participants during the breaks which were well supported and attended. 

Assistant Professor Edward Azawedo from Karolinska University Hospital, was one of the first to try NeoNavia clinically. We are really pleased that he also wants to participate in a workshop with us at home, in Sweden. 

List change to Nasdaq First North Growth Market

We're happy to be able to complete our plan and make a list change to the Nasdaq First North Growth Market. The reason for the list change was to make ourselves available to more people internationally. We are also preparing to take NeoNavia to the US market.